用于体外循环装置的材料涂层技术综述与展望

doi:10.11896/j.issn.1005-023X.2018.13.022

Abstract
Figure/Table
References
Related Citation (15)

Download:

Full Text ( PDF ) (1762KB)
Export: BibTeX | EndNote (RIS)

Abstract During the past several decades, the progress in techniques such as extracorporeal procedures including haemodialysis, cardiopulmonary bypass, as well as orthopedic, vascular and reconstructive surgery promoted the use of artificial materials in contact with living tissue dramatically. The evolution has highlighted the problems of biocompatibility. In the case of blood contact with any foreign materials induces activation of several host response defense mechanisms such as haemostatic mechanism, with consequences as thrombus formation, occlusion of medical device and embolization, which greatly limits the application of materials in medicine. Therefore, improving the biocompatibility of materials in cadiopulmonary Bypass system, especially the hemocompatibility, is the key to solve this problem. At present, the most effective and widely used technique for improving the biocompatibility of materials is surface coating technology. This paper reviews three main ways to improve the hemocompatibility of materials: build biological inert surface, bionic surface, and load bioactive substances, at the same time introduce several surface coating technologies and their clinical application, such as albumin, polyethylene oxide, SMA, PEMA, phosphorylcholine, glycosaminoglycan, heparin, hirudin, dipyridamole, and others. In the end, give a prospect of improving the hemocompatibility of cadiopulmonary bypass system.

Key words： coating cadiopulmonary bypass biocompatibility hemocompatibility anticoagulation heparin

Published: 01 August 2018

CLC number:

R318.08

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Tao
	WANG Ruibin
	HUO Feng

Cite this article:

JIANG Tao,WANG Ruibin,HUO Feng. The Review and Prospect of Cadiopulmonary Bypass Coating Materials[J]. Materials Reports, 2018, 32(13): 2304-2310.

URL:

http://www.mater-rep.com/EN/10.11896/j.issn.1005-023X.2018.13.022 OR http://www.mater-rep.com/EN/Y2018/V32/I13/2304

1 Mulvihill J N, Faradji A, Oberling F, et al. Surface passivation by human albumin of plasmaperesis circuits reduces platelet accumulation and thrombus formation. Experimental and clinical studies[J].Journal of Biomedical Materials Research Part A,1990,24(2):155.
2 Zimmermann A K, Weber N, Aebert H, et al. Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators[J].Journal of Biomedical Materials Research Part B: Applied Biomaterials,2007,80(2):433.
3 Sefton M V, Gemmel C H. Nonthrombogenic treatments and strategies.∥Buddy D, Ratner Allan S, et al. Biomaterials Science, Second Edition[M].Amsterdam:Elsevier Academic Press,2004:456.
4 Alcantar N A, Aydil E S, Israelachvili J N. Polyethylene glycol-coated biocompatible surfaces[J].Journal of Biomedical Materials Research Part B: Applied Biomaterials,2000,51:343.
5 Chen H, Zhang Z, Chen Y, et al. Protein repellant silicone surfaces by covalent immobilization of poly(ethylene oxide)[J].Biomaterials,2005,26(15):2391.
6 Goor V J, et al. Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response[J].European Journal of Cardio-Thoracic Surgery,2004,26:926.
7 Marcoux J, Sohn N, McNair E, et al. Outcomes comparison of 5 coated cardiopulmonary bypass circuits versus an uncoated control group of patients undergoing cardiac surgery[J].Perfusion,2009,24(5):307.
8 Eynden F V, Carrier M, Ouellet S, et al. Avecor trillium oxyge-nator versus noncoated monolyth oxygenator: A prospective randomized controlled study[J].Journal of Cardiac Surgery,2008,23(4):288.
9 Maria C T. Bioactive technologies for hemocompatibility[J].Expert Review of Medical Devices,2005,2(4):473.
10 Rubens F D, Labow R S, Lavallee G R, et al. Hematologic evaluation of cardiopulmonary bypass circuits prepared with a novel block copolymer[J].The Annals of Thoracic Surgery,1999,67(3):689.
11 Rubens F D, Ruel M, Lavallee G R, et al. Circuits with surface modifying additive alter the haemodynamic response to cardiopulmonary bypass[J].European Journal of Cardio-Thoracic Surgery,1999,15(3):353.
12 Newling R, Morris R. SMART tubing presents an increased risk of disconnection during extracorporeal circulation[J].The Journal of Extra-corporeal Technology,2005,37(4):400.
13 Suhara H, Sawa Y, Nishimura M, et al. Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model[J].The Annals of Thoracic Surgery,2001,71(5):1603.
14 Suzuki Y, Daitoku K, Minakwa M, et al. Poly-2-methoxyethylacrylate-coated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery[J].Journal of Artificial Organs,2008,11(3):111.
15 Itoh H, Ichiba S, Ujike Y, et al. A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass[J].Perfusion,2016,31(3):247.
16 Thiara A, Andersen V, Videm V, et al. Comparable biocompatibility of Phisio-and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response[J].Perfusion,2010,25(1):9.
17 Durrani A A, Hayward J A, Chapman D. Biomembranes as models for polymer surfaces Ⅱ: The syntheses of reactive species for covalent coupling of phosphorylcholine to polymer surfaces[J].Biomate-rials,1986,7(2),121.
18 Orban J M, Faucher K M, Dluhy R A, et al. Cytomimetic biomaterials. 4. In situ photopolymerization of phospholipids on an alkylated surface[J].Macromolecules,2000,33:4205.
19 Liu H, Faucher K M, Sun X L, et al. A membrane-mimetic barrier for cell encapsulation[J].Langmuir,2002,18:1332.
20 Ross E E, Bondurant B, Spratt T, et al. Formation of self-assembled, air-stable lipid bilayer membranes on solid supports[J].Langmuir,2001,17:2305.
21 Kolusheva S, Kafri R, Katz M, et al. Rapid colorimetric detection of antibody-epitope recognition at a biomimetic membrane interface[J].Journal of the American Chemical Society,2001,123:417.
22 Lee J H, Ju Y M, Kim D M. Platelet adhesion onto segmented pol-yurethane film surfaces modified by addition and crosslinking of PEO-containing block copolymers[J].Biomaterials,2000,21:683.
23 Iwasaki Y, Tojo Y, Kurosaki T, et al. Reduced adhesion of blood cells to biodegradable polymers by introducing phosphorylcholine moieties[J].Journal of Biomedical Materials Research Part A,2003,65:164.
24 Campbell E J, O’Byrne V, Stratford P W, et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer[J].Asaio Journal,1994,40(3):853.
25 Reser D, Seifert B, Klein M, et al. Retrospective analysis of outcome data with regards to the use of Phisio®-, Bioline®-or Softline®-coated cardiopulmonary bypass circuits in cardiac surgery[J].Perfusion,2012,27(6):530.
26 Lorusso R, De Cicco G, Totaro P, et al. Effects of phosphorylcholine coating on extracorporeal circulation management and postoperative outcome: A double-blind randomized study[J].Interactive Cardio Vascular and Thoracic Surgery,2009,8(1):7.
27 Karakisi S, Kunt A, Çankaya , et al. Do phosphorylcholine-coated and uncoated oxygenators differ in terms of elicitation of cellular immune response during cardiopulmonary bypass surgery?[J].Perfusion,2015,20(2):1.
28 Schulze C J, Han L, Ghorpade N, et al. Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG: A prospective randomized trial[J].Journal of Cardiac Surgery,2009,24(4):363.
29 Hoel T N, Thiara A S, Videm V, et al. In vitro evaluation of PHISIO-coated sets for pediatric cardiac surgery[J].Scandinavian Cardiovascular Journal,2009,43(2):129.
30 Lin H B, Garcia-Echeverria C, Asakura S, et al. Endothelial cell adhesion on polyurethanes containing covalently attached RGD-peptides[J].Biomaterials,1992,13:905.
31 Lin Y S, Wang S S, Chung T W, et al. Growth of endothelial cells on different concentrations of Gly-Arg-Gly-Asp photochemically grafted in polyethylene glycol modified polyurethane[J].Artificial Organs,2001,25:617.
32 Wang D, Feng L, Ji J, et al. Novel human endothelial cell-engineered polyurethane biomaterials for cardiovascular biomedical applications[J].Journal of Biomedical Materials Research Part A,2003,65A:498.
33 McClung W G, Clapper D L, Hu S P, et al. Lysine-derivatized pol-yurethane as a clot lysing surface: Conversion of adsorbed plasminogen to plasmin and clot lysis in vitro[J].Biomaterials,2001,22:1919.
34 Aldenhoff Y B, Koole L H. Platelet adhesion studies on dipyridamole coated polyurethane surfaces[J].European Cells and Materials,2003,5:61.
35 Frost M C, Reynolds M M, Meyerhoff M E. Polymers incorporating nitric oxide releasing/generating substances for improved biocompa-tibility of blood-contacting medical devices[J].Biomaterials,2005,26,1685.
36 Phaneuf M D, Berceli S A, Bide M J, et al. Covalent linkage of recombinant hirudin to poly(ethylene terephthalate) (Dacron): Creation of a novel antithrombin surface[J].Biomaterials,1997,18:755.
37 Wyers M C, Phaneuf M D, Rzucidlo E M, et al. In vivo assessment of a novel dacron surface with covalently bound recombinant hirudin[J].Cardiovascular Pathology,1999,8:153.
38 Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue[J].Biomaterials Medical Devices & Artificial Organs,1983,11:161.
39 Levy M, Hartman A R. Heparin-coated bypass circuits in cardiopulmonary bypass: Improved biocompatibility or not[J].International Journal of Cardiology,1996,53:S81.
40 Vocelka C, Lindley G. Improving cardiopulmonary bypass: Heparin-coated circuits[J].The Journal of Extra-corporeal Technology,2003,35(4):312.
41 Vroege R D, Stooker W, Oeveren W V, et al. The impact of heparin coated circuits upon metabolism in vital organs: Effect upon cerebral and renal function during and after cardiopulmonary bypass[J].Asaio Journal,2005,51(1):103.
42 Ovrum E, Tangen G, Tollofsrud S, et al. Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: An analysis of nearly 6000 patients undergoing coronary artery bypass grafting[J].The Journal of Thoracic and Cardiovascular Surgery,2011,141:1145.
43 Engbers G H, Feijen J. Current techniques to improve the blood compatibility of biomaterial surfaces[J].The International Journal of Artificial Organs,1991,14:199.
44 Tayama E, Hayashida N, Akasu K, et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: New heparin bonded bioline system[J].Artificial Organs,2000,24:618.
45 Palatianos G M, Foroulis C N, Vassili M I, et al. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit[J].The Annals of Thoracic Surgery,2003,761:129.
46 Ranucci M, Balduini A, Ditta A, et al. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome[J].The Annals of Thoracic Surgery,2009,87:1311.
47 Kreisler K R, Vance R A, Cruzzavala J, et al. Heparin-bonded cardiopulmonary bypass circuits reduce the rate of red blood cell transfusion during elective coronary artery bypass surgery[J].Journal of Cardiothoracic and Vascular Anesthesia,2005,19(5):608.
48 Wendel H P, Scheule A M, Eckstein F S, et al. Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces[J].Perfusion,1999,14(1):21.